HOMEPAGE La Fondazione Vincenzo Pansadoro Vito Pansadoro - Centro di Urologia Laparoscopica Cora Sternberg - Centro di Oncologia Medica Congressi Corsi Pubblicazioni Interventi di Urologia Laparoscopica Staff News Contatti
venerdì 10 settembre 2010
HOMEPAGE
English version
ABSTRACTS - FONDAZIONE VINCENZO PANSADORO
Pubblicazioni
Abstracts
Glossario


 

High-risk metastatic urothelial cancer: chances for cure?

Vincenzo Pansadoro Foundation, Clinic Pio XI, Via Aurelia 559, Rome, Italy 00165
The median survival of patients with metastatic bladder cancer treated with methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy is approximately 1 year and long-term survival occurs in a small proportion of patients. Recent efforts to improve the outcome of patients with metastatic transitional cell carcinoma have focused on the identification of new drugs with single agent activity and on their incorporation into platinum-based combination regimens. Paclitaxel, docetaxel, ifosfamide and gemcitabine are among the most active new agents. A large number of phase I/II trials have evaluated these agents in two- and three-drug combination regimens. The response proportion observed with these combinations varies considerably and median survival times range from 8 to 20 months. Because it is known that pretreatment prognostic features have an impact on individual patient outcome, the variation in reported survival in patients treated with chemotherapy may be a consequence of pretreatment patient characteristics. The role of surgery in metastatic bladder cancer is still controversial. After a significant response to chemotherapy, resection of residual resistant disease may be performed with intent to cure in highly selected patients. As obtainment of complete remission is a prerequisite for long-term survival, new therapeutic strategies, such as molecular targeted small molecule therapy and monoclonal antibodies, and new molecular markers predictive of response have the potential to be incorporated into the current treatment strategies, increasing the rate of cure.
Calabro F, Sternberg CN
Curr Opin Urol. 2002 Sep;12(5):441-8.

Back

IL SISTEMA ROBOTICO
DA VINCI
Scarica pdf

CONGRESSI DELLA FONDAZIONE

Challenges in Laparoscopy & Robotics 2010: The European Congress of Laparoscopy
Roma, 10-12 Giugno 2010
Challenges in Laparoscopy & Robotics 2009: Surgeons: Claude Abbou, Xavier Cathelineau, D. Cherqui, P. De Kuyper, A. Delataille, Vincenzo Disanto, Richard Gaston, Inderbir Gill, Giorgio Guazzoni, J. Hubert, Günter Janetschek, Alex Mottrie, Vito Pansadoro, Thierry Piechaud, Jens-Uwe Stolzenburg, Ingolf Türk, Roland Van Velthoven, Peter Wiklund
Parigi, 26 - 28, Maggio 2009
ALTRI CONGRESSI

ECCO 14
Barcellona, 23 - 27 Settembre 2007
home - la fondazione - centro di urologia laparoscopica - centro di oncologia medica - congressi - pubblicazioni - interventi - contatti
Copyright ©2004 all right reserved - Best viewed: Netscape - Explorer 5.5 or better - Websolution: Rita Maneri
Fondazione Vincenzo Pansadoro, Via Aurelia 559 Roma 00165 Tel.: +39 06 66418008 - +39 06 66416340
Fax: +39 06 6630771 - Email:info@fondazionevincenzopansadoro.com